Continuing medical educationFamilial skin cancer syndromes: Increased risk of nonmelanotic skin cancers and extracutaneous tumors
Introduction
Nonmelanoma skin cancers (NMSCs) represent the most common malignancies in the United States, making up 96% of all skin cancers and accounting for 2 to 3 million cases each year.1 Like melanoma, cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) represent complex diseases influenced by both the external environment and inherent genetics. While tumor development in both often occurs sporadically and is strongly associated with risk factors such as ultraviolet radiation, immunosuppression, viral infections, and radiotherapy, there is a subset of cases in which it occurs in the context of hereditary cancer syndromes. In general, these genetic syndromes fall under several broad categories: those associated with immunodeficiency, those that affect pigmentation, and those that perturb key molecular pathways involved in the pathogenesis of NMSCs. This article is an overview of the clinical features, epidemiology, evaluation, genetics, and management of the major hereditary genodermatoses with NMSC predisposition (Table I). While the risk of NMSC is increased in many hereditary conditions associated with immunodeficiency, this article focuses on those with the most direct risk of skin cancer.
Section snippets
Familial cancer syndromes and nonmelanoma skin cancer risk: Increased risk of basal cell carcinoma
Key points Basal cell nevus syndrome is an autosomal dominant syndrome driven by aberrant activation of the sonic hedgehog pathway; it is characterized by developmental defects and multiple neoplasms, including the development of numerous basal cell carcinomas Developmental defects in patients with basal cell nevus syndrome include palmar and plantar pits, craniofacial anomalies, corpus collosum dysgenesis, falx cerebri calcification, coarse facies, cleft palate, and spina bifida occulta Extracutaneous
Familial cancer syndromes and nonmelanoma skin cancer risk: Increased risk of squamous cell carcinoma
Key points There are numerous genodermatoses leading to an increased risk of squamous cell carcinoma; they primarily fall into 1 of the following categories: germline defects in DNA repair leading to increased genomic instability, defects in pigmentation, or defects in key signaling pathways involved in squamous cell carcinoma development Many of the genetic syndromes leading to an increased risk of squamous cell carcinoma are also characterized by an increased risk of other malignancies; therefore, a
Familial cancer syndromes and nonmelanoma skin cancer risk: Increased risk of other nonmelanoma skin cancers
Key points Adenosine deaminase severe combined immunodeficiency is a rare immunodeficiency syndrome that is associated with a high incidence of dermatofibrosarcoma protuberans; unlike dermatofibrosarcoma protuberans in the general population, dermatofibrosarcoma protuberans in patients with adenosine deaminase severe combined immunodeficiency typically demonstrates multicentricity and occurrence at an early age Muir–Torre syndrome is an autosomal dominant condition caused by germline mutations in mismatch
Conclusion
In conclusion, NMSCs are uncommon in pediatric patients, and the diagnosis of skin cancer at a young age often points to an underlying genetic condition. Recent advances in genomics promise to change the way in which these conditions are diagnosed and managed, and dermatologists play a critical role in this process. In general, genetic testing is used in 2 situations: (1) to confirm the clinical diagnosis of a genetic disease or (2) to predict the probability of a genetic condition in an
References (92)
- et al.
Location of gene for Gorlin syndrome
Lancet
(1992) - et al.
Nevoid basal cell carcinoma syndrome: a retrospective analysis of 33 affected Korean individuals
Int J Oral Maxillofac Surg
(2004) - et al.
Spectrum of PTCH1 mutations in French patients with Gorlin syndrome
J Invest Dermatol
(2003) - et al.
Treatment and prevention of basal cell carcinoma with oral isotretinoin
J Am Acad Dermatol
(1988) - et al.
The gene for Bazex-Dupre-Christol syndrome maps to chromosome Xq
J Invest Dermatol
(1995) - et al.
Rombo syndrome: a second case report and review
J Am Acad Dermatol
(1993) - et al.
Digenic/multilocus aetiology of multiple self-healing squamous epithelioma (Ferguson-Smith disease): TGFBR1 and a second linked locus
Int J Biochem Cell Biol
(2014) - et al.
Ferguson-Smith syndrome: the importance of long term follow-up
Br J Plast Surg
(1996) - et al.
Oculocutaneous albinism (OCA) in Colombia: first molecular screening of the TYR and OCA2 genes in South America
J Dermatol Sci
(2014) - et al.
The genetics of dyskeratosis congenita
Cancer Genet
(2011)
A gene for an autosomal dominant scleroatrophic syndrome predisposing to skin cancer (Huriez syndrome) maps to chromosome 4q23
Am J Hum Genet
Rothmund-Thomson syndrome
Dermatol Clin
The function of RecQ helicase gene family (especially BLM) in DNA recombination and joining
Adv Biophys
Surveillance and treatment of malignancy in Bloom syndrome
Clin Oncol
GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity
Blood
Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia
Blood
A 20-year perspective on the International Fanconi Anemia Registry (IFAR)
Blood
Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification
J Am Acad Dermatol
Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986-2006
J Am Acad Dermatol
Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants
J Pediatr
Genotype is an important determinant of phenotype in adenosine deaminase deficiency
Curr Opin Immunol
Multicentric dermatofibrosarcoma protuberans in patients with adenosine deaminase-deficient severe combined immune deficiency
J Allergy Clin Immunol
Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002
J Am Acad Dermatol
The Muir-Torre syndrome: a 25-year retrospect
J Am Acad Dermatol
“Second hit” in sebaceous tumors from Muir-Torre patients with germline mutations in MSH2: allele loss is not the preferred mode of inactivation
J Invest Dermatol
Muir-Torre phenotype has a frequency of DNA mismatch-repair-gene mutations similar to that in hereditary nonpolyposis colorectal cancer families defined by the Amsterdam criteria
Am J Hum Genet
Association of sebaceous gland tumors and internal malignancy: the Muir-Torre syndrome
Am J Med
Hereditary cancer syndromes of the skin
Clin Dermatol
A systematic review of worldwide incidence of nonmelanoma skin cancer
Br J Dermatol
Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib. A syndrome
N Engl J Med
The basal-cell nevus: its relationship to multiple cutaneous cancers and associated anomalies of development
AMA Arch Derm
Nevoid basal cell carcinoma syndrome. Clinical findings in 37 Italian affected individuals
Clin Genet
Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome
Am J Med Genet
Nevoid basal cell carcinoma syndrome: review of 118 affected individuals
Am J Med Genet
Nevoid basal-cell carcinoma syndrome
Med Baltim
Nevoid basal cell carcinoma syndrome: molecular biology and new hypotheses
Int J Oral Maxillofac Surg
Clinical findings in two African-American families with the nevoid basal cell carcinoma syndrome (NBCC)
Am J Med Genet
Gorlin-Goltz syndrome–a medical condition requiring a multidisciplinary approach
Med Sci Monit
Odontogenic keratocysts in nevoid basal cell carcinoma (Gorlin's) syndrome: CT and MRI evaluation
Ear Nose Throat J
Consensus statement from the first international colloquium on basal cell nevus syndrome (BCNS)
Am J Med Genet A
Basal cell carcinomas: attack of the hedgehog
Nat Rev Cancer
Most germ-line mutations in the nevoid basal cell carcinoma syndrome lead to a premature termination of the PATCHED protein, and no genotype-phenotype correlations are evident
Am J Hum Genet
Basal cell carcinomas in gorlin syndrome: a review of 202 patients
J Skin Cancer
Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations
J Clin Oncol
High frequency of germline SUFU mutations in children with desmoplastic/nodular medulloblastoma younger than 3 years of age
J Clin Oncol
A missense mutation in PTCH2 underlies dominantly inherited NBCCS in a Chinese family
J Med Genet
Cited by (38)
European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma—update 2023
2023, European Journal of CancerPediatric Cutaneous Oncology: Genodermatoses and Cancer Syndromes
2023, Dermatologic ClinicsTowards less mutilating treatments in patients with advanced non-melanoma skin cancers by earlier use of immune checkpoint inhibitors
2022, Critical Reviews in Oncology/HematologyCitation Excerpt :Patients with hereditary skin cancer syndromes and those receiving immunosuppressive medication are even at higher risk of developing multiple primary skin cancers. Examples of hereditary skin cancer syndromes are xeroderma pigmentosum (XP), basal cell nevus syndrome (BCNS), and epidermolysis bullosa (EB) (Jaju et al., 2016). A median of 160 BCCs (range: 0–2200) are diagnosed in the lifetime of a patient with BCNS (Solis et al., 2017).
A review of terms used to define cutaneous squamous cell carcinoma with a poor prognosis
2020, Actas Dermo-SifiliograficasDiagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines
2019, European Journal of CancerBasal cell carcinoma: Epidemiology; pathophysiology; clinical and histological subtypes; and disease associations
2019, Journal of the American Academy of DermatologyCitation Excerpt :Xeroderma pigmentosum, a group of inherited disorders characterized by impaired DNA repair and hypersensitivity to UV-induced mutagenesis, have an 1000-fold increased risk of cutaneous malignancies, including BCC. KCs begin to develop at median age of 8.5 years.136 Other genetic disorders characterized by increased BCC risk (but not necessarily as a prominent and specific finding) include diseases of DNA replication/repair functions (Werner, Rothmund–Thomson, Bloom, Werner, and Muir–Torre syndromes), immune response (cartilage-hair hypoplasia, epidermodysplasia verruciformis), folliculosebaceus unit (Brooke–Spiegler, Schöpf-Schulz-Passarge, and Cowden syndromes), melanin biosynthesis (oculocutaneous albinism and Hermansky–Pudlak syndrome), and epidermal nevus syndromes.141
Supported by a Stanford University Medical Scholars Research Fellowship (Ms Jaju) and the Howard Hughes Medical Institute (Ms Ransohoff).
Conflicts of interest: None declared.
Date of release: March 2016
Expiration date: March 2019